Send to

Choose Destination
Oncotarget. 2017 Aug 7;8(42):72197-72204. doi: 10.18632/oncotarget.20060. eCollection 2017 Sep 22.

MMP16 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.

Author information

Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Department of General Surgery, Yixing People's Hospital, Yixing, Wuxi 214200, China.


Matrix metalloproteinase (MMPs) participates in multiple biological behaviors and plays an important role in regulating tumor invasion. However, the functions of MMP16 in hepatocellular carcinoma (HCC) remains unknown. The prognostic value of MMP16 was studied in TCGA database and validation cohort. MMP16-silencing HCC cells (HepG2 and HCCLM3) were used for evaluating cell proliferation and invasion by CCK-8 and Transwell assays. Our results showed that the MMP16 was a predictor for overall survival in patients with HCC (HR: 1.169, 95% CI: 1.034-1.321, P = 0.013) in TCGA database. In validation cohort, MMP16 expression was an independent predictor for survival in both univariate and multivariate analysis (P < 0.05). Furthermore, knockdown MMP16 weakened the cell invasive potential by inhibiting epithelial-mesenchymal transition (EMT) process. Therefore, our findings showed that MMP16 was a prognostic factor in HCC, ectopic MMP16 expression promoted invasion of HCC cells by inducing EMT process, suggesting a tumor oncogenic function in HCC and provides the potential therapeutic target for the treatment of HCC.


MMP16; TCGA; epithelial-mesenchymal transition; hepatocellular carcinoma; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST None of the authors have any conflicts of interest to declare.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center